Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Safety, and Tolerability of DITEST in Adult Men With Hypogonadism
NCT02966652Phase 1Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Nov 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DITEST in male hypogonadism (2 cohorts), sponsored by Neurocrine Biosciences. Primary endpoints: Peak Plasma Concentration and Area under the serum testosterone concentration-time curve from time 0-10. Started Nov 2016; status: completed.
02
Drugs
DITEST
03
Conditions
male hypogonadism
Beyond the preview
Go deeper on NCT02966652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02966652.